GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

XBIO · Dec 31, 2025

Xenetic Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001683168-26-001737General Corporate
Operating cash generation80thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-76.83% · OPTIONAL · VALID

Revenue growth44thOwn-history percentile · N=16
Evidence method

Yoy · gp.fundamentals.revenue

19.04% · CORE · VALID

Operating margin90thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

-95.23% · CORE · VALID

R&D intensity20thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

102.99% · OPTIONAL · VALID

SBC intensity5thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

2.18% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History19 statesSelf-history eligible
Period transition

What moved in the state?

Cash Generation Decreased
Previous
-64.10%
Current
-76.83%
Delta
-12.73%
Growth Decreased
Previous
67.19%
Current
19.04%
Delta
-48.15%
Profitability Decreased
Previous
-53.04%
Current
-95.23%
Delta
-42.19%
R And D Intensity Increased
Previous
73.66%
Current
102.99%
Delta
29.33%
Sbc Intensity Increased
Previous
1.54%
Current
2.18%
Delta
0.63%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.